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Abstract The purpose of this study was to determine the
clinical and microbiological risk factors for treatment failure
of methicillin-resistant Staphylococcus aureus (MRSA)
orthopedic device-related infection (ODRI). A retrospective
cohort study of patients with MRSA ODRI who were treated
at Geneva University Hospitals between 2000 and 2008 was
undertaken. Stored MRSA isolates were retrieved for genetic
characterization and determination of the vancomycin
minimum inhibitory concentration (MIC). Fifty-two patients
were included, of whom 23 (44%) had joint arthroplasty and
29 (56%) had osteosynthesis. All 41 of the retrieved MRSA
isolates were susceptible to vancomycin (MIC≤2 mg/L) and
35 (85%) shared genetic characteristics of the South German
clone (ST228). During a median follow-up of 391 days
(range, 4–2,922 days), 18 patients (35%) experienced
treatment failure involving MRSA persistence or recurrence.
This study has been presented at the 49th ICAAC Meeting (12–15
September 2009, San Francisco, CA, USA) as a poster presentation
(Poster K-963).
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Microbiological factors such as infection with the predom-
inant clone and a vancomycin MIC of 2 mg/L were not
associated with treatment failure. Using a Cox proportional
hazards model, implant retention (hazard ratio [HR], 4.9;
95% confidence interval [CI], 1.3–18.2; P=0.017) and
single-agent antimicrobial therapy (HR, 4.4; 95% CI,
1.2–16.3; P=0.025) were independent predictors of treat-
ment failure after debridement. Therapy using a combina-
tion of antimicrobials should be considered for patients
with MRSA ODRI, especially when implant removal is
not feasible.
Introduction
Orthopedic device-related infections (ODRI, including joint
arthroplasty infections and infections of other orthopedic
hardware, such as osteosynthesis) are infrequent, but are
potentially severe and costly [1–3]. Staphylococcus aureus,
which can persist within the implant site by producing a
biofilm or variant microcolonies, is one of the most
frequently associated bacteria with ODRI [4–8]. These
infections are difficult to cure and relapse can occur many
years after the initial episode [1–3, 9–11].
The management of ODRI, whatever the type of ODRI
(i.e., joint arthroplasty infections or infections of other
orthopedic hardware), globally includes surgery (debride-
ment with or without implant removal) and lengthy
antimicrobial therapy [2]. Treatment failure is nine times
more frequent in patients with prosthetic joint infections
due to hospital-acquired methicillin-resistant S. aureus
(MRSA) than in patients suffering from methicillin-
susceptible S. aureus (MSSA) infection [12]. MRSA ODRI
is considered to be difficult to treat, as: (1) the bacterium is
usually resistant to many clinically important non-beta-
lactam drugs, such as fluoroquinolones and clindamycin,
that have excellent bone penetration and are usually
recommended for the treatment of staphylococcal bone
and joint infections; and (2) vancomycin, which is largely
used to treat MRSA infections, has slow bactericidal
activity, and treatment failure is not uncommon, even when
strains are fully susceptible (minimum inhibitory concen-
tration [MIC] ≤2 mg/L) [13]. Moreover, it has been recently
suggested that pandemic MRSA clones (usually character-
ized by multilocus sequence typing [MLST]) responsible
for such hospital-acquired ODRI might have advantageous
virulence properties (such as an enhanced biofilm produc-
tion, as described for the predominant clone in Brazil) that
may facilitate infection and hinder eradication [14–16]. The
influence on the outcome of particular clonal character-
istics, as well as the pre-therapy vancomycin MIC and the
different treatment options, is poorly documented in
patients with MRSA ODRI.
The objectives of this study were: (1) to describe the
clinical characteristics, surgical and medical therapy, and
outcome of patients with MRSA ODRI managed at our
institution; (2) to genetically characterize each MRSA
isolate and to determine the vancomycin MIC at the onset
of therapy in order to identify microbiological and clinical
risk factors for treatment failure.
Materials and methods
Patients and setting
Geneva University Hospitals is a 2,200-bed institution
admitting about 40,000 patients annually. We conducted a
retrospective cohort study of patients who had at least one
episode of MRSA ODRI between 2000 and 2008. The
databases of the bacteriology laboratory, the orthopedic
sepsis cohort study, the arthroplasty cohort study, and the
hospital’s administrative coding system were used for
patient selection. The study was approved by the local
ethics committee, waiving the need for informed consent.
Data collection
Data were collected from medical reports and nursing
charts. In order to limit loss to follow-up, patients or their
family were contacted by telephone and interviewed about
the outcome of their infection. If direct contact was not
possible, outcome information was sought through health-
care providers.
Inclusion criteria and definitions
Patients fulfilling all of the following criteria were included
in the study: (1) local and/or systemic clinical signs of acute
or chronic bone infection (pain and/or tenderness, fever,
swelling, heat, erythema, purulent discharge, sinus tract);
(2) presence of an implanted device at the site of infection;
and (3) MRSA culture from a preoperative specimen (such
as aspirated synovial fluid, needle aspirate of a sinus tract,
or blood culture associated with clinical evidence that the
implant was the primary site of infection) or from intra-
operative specimens. Histological confirmation was not
required for the diagnosis of bone infection. The infection
was considered to be ‘acute’ when symptoms lasted
≤30 days and ‘late’ when occurring more than 30 days
prior to admission [2]. Hematogenous infection was
diagnosed when the implant site became infected following
MRSA bacteremia associated with another initial site of
infection. Persistent MRSA infection was recorded if the
patient’s clinical status required further surgery five days
after initial therapy, with isolation of the same MRSA strain
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by intraoperative specimen culture. Recurrence was defined
as resurgence of the infection with the same MRSA strain
after the end of antimicrobial therapy. Treatment failure was
recorded in case of persistent infection, recurrence, super
infection (infection during treatment of the initial episode),
or reinfection (infection after successful treatment of the
initial episode) by another pathogen, limb loss, or death
from ODRI. Treatment failure involving MRSA was
defined as persistent infection, recurrence, limb loss due
to MRSA ODRI, or death directly related to MRSA ODRI.
The Charlson comorbidity index was calculated as de-
scribed elsewhere [17]. Combination antimicrobial therapy
was defined as a combination of two MRSA-active agents
administered for at least one day during the initial ODRI
episode. The defined daily dose (DDD) of each adminis-
tered drug was calculated using current guidelines for the
treatment of MRSA bone and joint infections [18].
Microbiological methods
MRSA was identified according to Clinical and Laboratory
Standard Institute (CLSI) recommendations [19]. We
retrieved MRSA isolates associated with implant-
associated infections that had been stored in skimmed
milk/glycerol at −80°C. A dendrogram was constructed for
MRSA isolates responsible for the initial infection by using
an automated variable number of tandem repeats (VNTR)
method (Bioanalyzer Experiments Clustering Software)
[20]. Isolates were further genotyped in terms of the
accessory gene regulator (agr) allele and SCCmec typing,
as appropriate (this analysis was restricted to a minimal
number of strains when isolates were considered to be
clonal according to the dendrogram) [21–23]. spa typing
was performed with the Ridom Staph Type standard
protocol (http://www.ridom.de) and the Ridom SpaServer,
which assigns spa types (http://spa.ridom.de/index.shtml)
and related sequence types (STs). Isolates sharing spa type
t041 or relatives, agr type 2, and SCCmec type I were
considered to belong to the so-called ‘South German’ clone
ST228 [14, 24, 25]. MRSA isolates isolated during
persistent or recurrent ODRI were considered to be
identical to the isolate responsible for the initial episode
when they had a percentage of similitude of 90% or above.
The vancomycin MIC was determined for all pre-therapy
isolates by using the Mueller–Hinton broth macrodilution
method, as recommended by the CLSI [19]. Isolates with
vancomycin MICs ≥4 mg/L and <16 mg/L were defined as
glycopeptide-intermediate S. aureus (GISA).
Statistical analysis
In the descriptive analysis, the Chi-square test or Fisher’s
exact test was used for categorical variables, as appropriate.
For the percentage calculation of each variable, the number
of missing values were excluded from the denominator. The
non-parametric Mann–Whitney test was used for continu-
ous variables. Kaplan–Meier failure curves were compared
between groups by using the log-rank test. Independent risk
factors for treatment failure involving MRSA (i.e., persis-
tence or recurrence of the MRSA infection) were deter-
mined by using a stepwise Cox proportional hazards model.
Variables with P-values<0.15 were included in the multi-
variate model. Variables were checked for interaction,
confounding, and collinearity. To avoid overfitting, a ratio
of 10 failures per independent variable was adopted. The
model was validated by testing the proportional hazards
assumption [26]. Statistical analysis was performed with
SPSS software version 15.0 (SPSS, Chicago, IL).
Results and discussion
Patient characteristics
Fifty-two patients met the inclusion criteria. All but two of
the patients had previously undergone implant surgery in
Geneva. Twenty-three patients (44%) had had joint arthro-
plasty (18 hip and five knee prostheses) and 29 patients
(56%) had other implants (including 23 internal fixation
devices, three centromedullar nails, and three external
fixation pins) infected by MRSA. The median follow-up
was 391 days (range, 4–2,922 days)
Comparison of patient groups
Patients with joint arthroplasty MRSA infection were older
(P=0.009) and had greater comorbidity (P=0.015) than
patients with osteosynthesis material-related MRSA infec-
tion (Table 1). Patients with osteosynthesis had longer
surgery (P=0.041) and more frequent emergency surgery
(P=0.038). No significant differences in surgical treatment,
antimicrobial therapy, or outcome were noted between
these two populations, which were merged for the analysis
of risk factors for treatment failure (Table 2).
Microbiology
MRSAwas retrieved from 41 (79%) of the 52 patients with
implant-associated infections. The sources were mainly
intraoperative specimens (30 isolates), blood (five isolates),
aspirated synovial fluid (four isolates), an abscess (one
isolate), and sterile aspiration of a sinus tract (one isolate).
Thirty-five isolates (85%) were clonally related and shared
microbiological characteristics of the South German MRSA
clone (spa type t041 or relatives, SCCmec type I, agr type
2; Fig. 1). All of these isolates shared a similar suscepti-
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Table 1 Characteristics and outcome of patients with methicillin-resistant Staphylococcus aureus (MRSA) orthopedic device-related infection
(ODRI) and comparison of patients with joint arthroplasty and patients with osteosynthesis
Characteristic Patients with joint
arthroplasty (n=23)
Patients with
osteosynthesis (n=29)
Total (n=52) P-value
Demographic characteristics
Age (median, IQR) 80 (71–88) 69 (46–81) 75 (59–83) 0.009
Male sex 14 (60.9) 13 (44.8) 27 (51.9) 0.250
Underlying conditions
At least one underlying illness 20 (87.0) 15 (53.6) 35 (68.6) 0.015
Diabetes mellitus 4 (17.4) 2 (6.9) 6 (11.5%) 0.387
Charlson comorbidity index (mean ± SD) 1.74 (1.25) 1.24 (1.55) 1.46 (1.43) 0.058
Data at the time of material insertion
Elective surgery 10 (43.5) 5 (17.2) 15 (28.8) 0.038
Duration of surgery in minutes (median, IQR) 110 (90–140) 143 (103–218) 120 (95–180) 0.041
Pre-existing MRSA colonization 3 (21.4) 5 (50.0) 8 (33.3) 0.204
Inappropriate antimicrobial prophylaxis 8 (50.0) 3 (12.0) 11 (26.8) 0.012
Interval in days between implant
insertion and infection (median, IQR)
16 (10–96) 28 (9–83) 20 (10–92) 0.691
Interval in days between first symptoms
and surgical treatment (median, IQR)
8 (4–17) 5 (3–17) 7 (3–17) 0.444
Type of osteomyelitis
Early postoperative (<1 month) 15 (65.2) 17 (58.6) 32 (61.5) 0.627
Late postoperative (>1 month to 1 year) 6 (26.1) 11 (37.9) 17 (32.7) 0.366
Hematogenous 2 (8.7) 1 (3.4) 3 (5.8) 0.577
Microbiological characteristics
Concomitant symptomatic MRSA bacteremia 7 (13.5) 6 (11.5) 13 (25.0) 0.605
Coinfection with another pathogena 2 (8.7) 5 (17.2) 7 (13.5) 0.444
Drug susceptibility of the MRSA isolate
Ofloxacin susceptible 0 (0) 1 (3.3) 1 (1.9) 1
Clindamycin susceptible 1 (4.3) 3 (10.3) 4 (7.7) 0.621
Rifampin susceptible 22 (95.7) 29 (100) 51 (98.1) 0.442
Fusidic acid susceptible 22 (95.7) 28 (96.6) 50 (96.2) 1
Initial surgical treatment with debridement 23 (100.0) 24 (82.8) 47 (90.4) 0.059
Debridement and retention of the implant 14 (60.9) 14 (58.3) 28 (53.8) 0.859
One-stage replacement 3 (13.0) 6 (25.0) 9 (19.1) 0.461
Removal of the implant 6 (26.1) 4 (16.7) 10 (21.3) 0.494
Retention of the implant with or
without debridement
14 (60.9) 19 (65.5) 33 (63.5) 0.730
Antibiotic therapy for the initial episode
Vancomycin 23 (100.0) 27 (93.1) 50 (96.2) 0.497
Rifampin 12 (52.2) 12 (41.4) 24 (46.2) 0.438
Fusidic acid 5 (21.7) 7 (24.1) 12 (23.1) 0.838
Cotrimoxazole 7 (30.4) 7 (24.1) 14 (26.9) 0.611
Other antibiotics (including linezolid) 5 (21.7) 2 (6.9) 7 (13.5) 0.219
Outcome
Treatment failure 13 (56.5) 13 (44.8) 26 (50.0) 0.402
Treatment failure involving MRSA 8 (34.8) 10 (34.5) 18 (34.6) 0.982
Persistent MRSA infection 6 (26.1) 4 (13.8) 10 (19.2) 0.307
Recurrent MRSA infection 2 (8.7) 6 (20.7) 8 (15.4) 0.278
Multiple treatment failure 7 (30.4) 7 (24.1) 14 (26.9) 0.611
Multiple treatment failure involving MRSA 6 (26.1) 3 (10.3) 9 (17.3) 0.161
Limb loss 2 (8.7) 2 (7.1) 4 (7.8) 1
174 Eur J Clin Microbiol Infect Dis (2010) 29:171–180
bility pattern, being resistant to gentamicin, erythromycin,
lincomycin, and fluoroquinolones. No GISA strain was
detected.
Surgical treatment and antimicrobial therapy
Surgical treatment consisted of debridement in 47 patients
(90%), with implant retention in 28 patients, device
explantation in ten patients, and one-stage exchange in
nine patients. None of the patients had two-stage exchange,
as the four patients scheduled for two-stage exchange
experienced treatment failure or had other conditions that
prevented reimplantation. Twenty-six patients (50%) re-
ceived only single-agent antimicrobial therapy (vancomycin
alone, cotrimoxazole alone, or vancomycin alone followed
by cotrimoxazole or linezolid). The other 26 patients (50%)
received combination antimicrobial therapy: 12 patients
received rifampin plus fusidic acid (with vancomycin-
rifampin as the initial therapy), eight patients received
vancomycin plus rifampin, four patients received rifampin
plus cotrimoxazole (with vancomycin-rifampin as the initial
therapy), and two patients received vancomycin plus
cotrimoxazole.
Univariate and multivariate survival analyses
Patients with and without treatment failure are compared in
Table 2. The Kaplan–Meier probability estimates of the
two-year failure rate were higher when the implant was left
in place than when it was removed (log-rank test: P=0.036;
Fig. 2, panel A). The estimates were lower in patients
receiving rifampin plus fusidic acid than in patients
receiving single-agent therapy and in patients receiving
other combinations (log-rank test: P=0.036 and P=0.010,
respectively; Fig. 2, panel B). In the subpopulation of
patients who underwent debridement with implant reten-
tion, the two-year probability of treatment failure was 83%
with single-agent therapy and 22% with combination
therapy (log-rank test: P=0.020; Fig. 3). The incidence
rate of failure involving MRSA in patients who had
debridement with implant retention was 3.1 per 100
patient-months in patients treated with single-agent therapy
and 1.4 per 100 patient-months in patients treated with an
antimicrobial combination, giving an incidence rate ratio of
2.3 (confidence interval [CI], 0.55–13.51; P=0.11). There
was a non-significant trend towards a higher probability of
treatment failure in patients infected by the predominant
South German clone ST228 in comparison with patients
infected by sporadic MRSA strains. There was no differ-
ence in the likelihood of failure according to the vancomy-
cin MIC (2 mg/L versus <2 mg/L).
In multivariate Cox analyses, after exclusion of the five
patients who did not receive a surgical debridement,
implant retention and single-agent therapy were the only
two independent variables associated with treatment failure
involving MRSA at two years (hazard ratio [HR], 4.90;
95% CI, 1.32–18.17; P=0.017 and HR, 4.43; 95% CI,
1.20–16.33; P=0.025, respectively) (Table 3).
Discussion
In this retrospective cohort study of patients with orthopedic
device-related MRSA infection during the period 2000–
2008, most isolates belonged to the South German clone
(ST228) and were fully susceptible to vancomycin (MIC≤
2 mg/L). Only single-agent antibacterial therapy and implant
retention were identified as independent risk factors for
treatment failure involving MRSA persistence or recurrence
at two years, after a median follow-up of 391 days.
Most nosocomial infections worldwide are due to a few
hospital-acquired MRSA clones [15]. In our institution, the
South German clone is endemic since 1999 [24, 25].
Amaral et al. recently found evidence that the predominant
Table 1 (continued)
Characteristic Patients with joint
arthroplasty (n=23)
Patients with
osteosynthesis (n=29)
Total (n=52) P-value
Death 9 (39.1) 4 (13.8) 13 (25.0) 0.054
Death from implant-associated infection 2 (8.7) 2 (6.9) 4 (7.7) 1
Follow-up
Follow-up in days (median, IQR) 181 (77–596) 490 (232–1,011) 391 (110–879) 0.058
Follow-up of at least three months 14 (60.9) 25 (86.2) 39 (75.0) 0.054
Data are numbers (%) unless otherwise indicated. Missing values were excluded from the calculation ofpercentages and the statistical
analysis. SD standard deviation; IQR interquartile range
a Including two coagulase-negative staphylococci, two Pseudomonas aeruginosa, one Enterobacter cloacae, one Streptococcus spp., and one
Enterococcus faecalis coinfections
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Table 2 Comparison of patients with MRSA ODRI with and without treatment failure directly attributed to MRSA
Variable Patients with MRSA
treatment failure (n=18)
Patients without MRSA
treatment failure (n=34)
Total (n=52) P-value
Demographic characteristics
Age (median, IQR) 71 (55–80) 78 (64–85) 75 (59–83) 0.154
Male sex 8 (44.4) 19 (55.9) 27 (51.9) 0.432
Underlying conditions
At least one underlying illness 9 (50.0) 26 (78.8) 35 (68.6) 0.057
Charlson comorbidity index (mean ± SD) 0.94 (1.43) 1.74 (1.38) 1.46 (1.43) 0.058
Data at the time of material insertion
Prior bone surgery 3 (16.7) 4 (11.8) 7 (13.5) 0.682
Elective surgery 6 (33.3) 9 (26.5) 15 (28.8) 0.603
Duration of surgery > 120 min 9 (69.2) 10 (38.5) 19 (48.7) 0.070
Pre-existing MRSA colonization 1 (11.1) 7 (46.7) 8 (33.3) 0.178
Inappropriate antimicrobial prophylaxis 2 (14.3) 9 (33.3) 11 (26.8) 0.275
Serum glucose (median, IQR) 6.7 (5.9–7.5) 6.4 (5.7–7.5) 6.4 (5.8–7.4) 0.858
Interval between material implantation and infection
In days (median, IQR) 31 (14–206) 17 (9–35) 20 (10–92) 0.058
> 3 months 7 (41.2) 4 (11.8) 11 (21.6) 0.028
Clinical data
Sinus tract 5 (27.8) 7 (20.6) 12 (23.1) 0.558
Abscess 2 (11.1) 7 (20.6) 9 (17.3) 0.470
Arthritis 5 (27.8) 21 (35.3) 27 (32.7) 0.583
Microbiological characteristics
Concomitant symptomatic MRSA
bacteremia
4 (33.3) 9 (47.4) 13 (41.9) 0.484
Coinfection by another pathogen 2 (11.1) 5 (14.7) 7 (13.5) 1
Suction drainage culture-positive for MRSA 5 (71.4) 5 (50.0) 10 (58.8) 0.622
Isolates belonging to the South German clone 16 (88.9) 18 (78.3) 34 (82.9) 0.679
Isolates with vancomycin MIC of 2 mg/L 9 (52.9) 15 (62.5) 24 (58.5) 0.540
Isolates belonging to the South German
clone (MVLA) with vancomycin of 2 mg/L
10 (55.6) 12 (52.2) 22 (53.7) 0.938
Interval between first symptoms and surgical treatment
In days (median, IQR) 7 (4–17) 8 (3–17) 7 (3–16) 0.992
> 8 days 5 (33.3) 12 (36.4) 17 (32.7) 0.839
Initial surgical treatment with debridement 14 (77.8) 33 (97.1) 47 (90.4) 0.043
Incomplete surgical debridement or
large tissue damage
4 (28.69) 5 (15.2) 9 (19.1) 0.419
Debridement plus retention of the implant 11 (78.6) 17 (51.5) 28 (59.6) 0.084
Partial or total one-stage replacement 1 (7.1) 8 (24.2) 9 (19.1) 0.244
Debridement and removal of the implant 2 (14.3) 8 (24.2) 10 (21.3) 0.700
Patients with retention of the implant
(with or without debridement)
15 (83.3) 18 (52.9) 33 (63.5) 0.030
Antibiotic therapy of the initial episode
Active combination antimicrobial therapy 6 (33.3) 20 (58.8) 26 (50.0) 0.080
Vancomycin 17 (94.4) 33 (97.1) 50 (96.2) 1
Teicoplanin 1 (5.6) 4 (11.8) 5 (9.6) 0.648
Rifampin 4 (22.2) 20 (58.8) 24 (46.2) 0.019
Fusidic acid 0 (0.0) 12 (35.3) 12 (23.1) 0.004
Dual-agent therapy with rifampin plus
fusidic acid
0 (0.0) 12 (35.3) 12 (23.1) 0.004
Cotrimoxazole 6 (33.3) 8 (23.5) 14 (26.9) 0.448
Other antibiotics (including linezolid) 1 (5.6) 6 (17.6) 7 (13.5) 0.399
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MRSA clone in Brazil exhibited particular virulence
properties [16]. In this study, by comparison with sporadic
MRSA isolates, isolates belonging to the Brazilian clone
were more adhesive and had a higher capacity to produce
biofilm in vitro. Here, we detected a non-significant trend
toward worse outcome among patients with isolates
belonging to the South German clone. Common MRSA
isolates are usually fully susceptible to vancomycin (MIC≤
2 mg/L), but small increases in the vancomycin MIC,
remaining within the range of susceptibility (from 1 to
2 mg/L, for example), were recently shown to influence the
outcome of bacteremia [13, 27]. Studies on vancomycin
pharmacodynamics revealed that such an MIC increase in
the range of susceptibility might have implications for
localized orthopedic infections, as vancomycin penetration
into bone is not optimal (bone-to-serum ratio 0.3) [28, 29].
Table 2 (continued)
Variable Patients with MRSA
treatment failure (n=18)
Patients without MRSA
treatment failure (n=34)
Total (n=52) P-value
Duration of antimicrobial therapy in days
(median, IQR)a
48 (35–87) 60 (41–88) 57 (41–88) 0.575
Duration of combination antimicrobial
therapy in days (median, IQR)a
34 (6–80) 29 (21–78) 29 (19–78) 0.629
Follow-up
Follow-up in days (median, IQR) 429 (136–1,481) 270 (95–837) 391 (110–878) 0.295
Data are numbers (%) unless otherwise indicated. Missing values were excluded from the calculation ofpercentages and statistical analysis. IQR
interquartile range
a After exclusion of the six patients with persistent MRSA infection for whom the duration of antimicrobial therapy priorto persistence were not
taken into account
Fig. 1 Genetic characterization and vancomycin minimum inhibitory
concentrations (MICs) of the 41 methicillin-resistant Staphylococcus
aureus (MRSA) isolates responsible for orthopedic device-related
infection (ODRI) in Geneva between 2000 and 2008. Isolates in bold
were considered to belong to the South German clone
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However, we found no significant difference in outcome
according to the vancomycin MIC.
Surgery is the cornerstone of the treatment of implant-
associated orthopedic infections. Retention of the implant
is considered, nowadays, as a possible surgical option.
This surgical procedure: (1) has to be performed if the
pathogen is fully susceptible to antimicrobial agents; (2)
has to be reserved for patients with a duration of
symptoms <3 weeks and with a stable implant without
soft-tissue damage nor sinus tract involvement; and (3)
requires a rigorous debridement [2, 3]. For staphylococcal
ODRI, only a few studies are available and most of them
included methicillin-susceptible isolates. For instance, in
the study performed by Brandt et al. that included 33
patients with S. aureus prosthetic joint infections treated
by debridement with prosthesis retention, the two-year
probability of treatment failure was 69%, but only one
isolate was methicillin-resistant [30]. More recently,
Marculescu et al. found a two-year treatment failure rate
of 40%, but, again, only one of the 32 S. aureus infections
was due to MRSA [31]. Even though data on MRSA
ODRI are lacking, complete implant removal is strongly
recommended for MRSA ODRI [1–3]. Our study, which
exclusively involved MRSA, definitively demonstrated
Fig. 3 Kaplan–Meier probability estimates of the 2-year failure rate in
the 28 patients with MRSA ODRI after surgical debridement with
implant retention, treated with single-agent or combination antimicro-
bial therapy
Fig. 2 Kaplan–Meier probabili-
ty estimates for the 2-year fail-
ure rate in the 52 patients with
MRSA ODRI. A Treated with
implant retention (including five
patients without surgical de-
bridement) or implant removal.
B Treatment with single-agent
therapy or with rifampin-fusidic
acid or with another combina-
tion antimicrobial therapy,
regardless of the surgical treat-
ment (*P=0.010 and **P=
0.036, log-rank test)
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that implant removal is required for the treatment of
MRSA ODRI, as implant retention clearly emerged as an
independent risk factor for treatment failure.
Antimicrobial therapy should always be combined with
surgery for the treatment of ODRI [1–3]. Only one
randomized double-blind placebo-controlled trial has dem-
onstrated the superiority of combination therapy with
rifampin (plus ciprofloxacin) over single-agent therapy
(ciprofloxacin) for the treatment of staphylococcal ODRI
[32]. It is noteworthy that, in this study, only two isolates
(two coagulase-negative staphylococci) were resistant to
methicillin. Since this landmark study, and since it has been
demonstrated that rifampin was also effective on bacteria
embedded in biofilm, rifampin-based combinations have
been considered as standard therapy for MRSA ODRI [2, 3,
33]. Few studies have compared different rifampin-based
regimens in staphylococcal ODRI. Drancourt et al. demon-
strated that a combination of rifampin and fusidic acid or
ofloxacin was similarly effective and well tolerated during
staphylococcal ODRI, but all of the isolates were
methicillin-susceptible [34]. To our knowledge, different
rifampin-based regimens have not been compared in
MRSA ODRI. In our study, it is noteworthy that none of
the patients who received combination therapy with
rifampin plus fusidic acid experienced treatment failure.
Controlled trials are needed to confirm the superiority of
the rifampin-fusidic acid combination for the treatment of
MRSA ODRI.
This study has some limitations. First of all, the
combination of joint arthroplasty infections with other
orthopedic hardware infections is criticable. Indeed, the
type, the surface of the hardware, the long-term surgical
implications, and the outcome might be different in these
two subgroups of patients. However, our cohort of patients
is microbiologically homogeneous, as all of them were
infected with MRSA, and guidelines for the initial
treatment of joint arthroplasty or other orthopedic hardware
infections are globally similar (i.e., surgery including
debridement with or without implant retention with antimi-
crobial therapy) [2]. Secondly, our study has the inherent
limitations of all retrospective observational cohort studies.
This was a single-center study, and the surgical and medical
management of ODRI likely evolved during the eight-year
study period. Thirdly, many patients were considered to be
lost to follow-up at two years, as a quarter of them, enrolled
after 2006, did not have a complete follow-up at the end of
the study in 2008. Finally, patients with treatment failure
occurring in another hospital may have been undetected.
However, since the Geneva University Hospitals is, by far,
the largest hospital in the area, we consider this latter
possible selection bias as minimal.
In contrast, to our knowledge, this is the first study that
examined microbiological and clinical risk factors of
treatment failure specifically for MRSA ODRI. Indeed,
the few previous reports of risk factors for treatment failure
in staphylococcal ODRI included mainly MSSA isolates.
In conclusion, we observed a treatment failure rate of
35% in a cohort of patients with orthopedic device-related
MRSA infection. Implant retention and single-agent anti-
microbial therapy were the only independent risk factors for
treatment failure. Microbiological factors, such as infection
by the South German clone and a vancomycin MIC of
2 mg/L, were not associated with treatment failure. Therapy
using a combination of antimicrobials should be considered
for patients with MRSA ODRI, especially when implant
removal is not feasible.
Table 3 Multivariable Cox regression model after exclusion of the five patients who did not receive a surgical debridement: independent factors
associated with treatment failure involving MRSA in patients with MRSA ODRI
Variable HR 95% CI P-value Adjusted HR 95% CI P-value
Agea 0.98 0.958–1.009 0.726
Charlson comorbidity indexb 0.71 0.477–1.066 0.099
Sinus tracta 0.93 0.327–2.625 0.886
Occurrence of ODRI >3 months after material insertion 2.47 0.936–6.494 0.068 2.43 0.784–7.511 0.124
Duration of symptoms prior to ODRI surgery >8 daysa 1.67 0.591–4.718 0.333
Duration of surgery for the episode of ODRI >120 mina 2.19 0.673–7.146 0.192
Glycemia in the 24 h prior to ODRI surgerya 0.72 0.452–1.153 0.173
Retention of the implant after surgical debridement 3.07 0.853–11.067 0.086 4.90 1.322–18.166 0.017
Intermittent vancomycina infusion 1.79 0.676–4.741 0.241
Single-agent antimicrobial therapy 2.39 0.896–6.386 0.082 4.43 1.203–16.329 0.025
HR hazard ratio; CI confidence interval
a Variables not included in the multivariate Cox regression model (P>0.15)
b Variable not included in the multivariate analysis, in order to avoid overfitting
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